sb 203580 has been researched along with Osteopetrosis in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ostrowski, MC; Patel, K; Rosol, TJ; Sankar, U | 1 |
1 other study(ies) available for sb 203580 and Osteopetrosis
Article | Year |
---|---|
RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
Topics: Acid Phosphatase; Alkaline Phosphatase; Animals; Blotting, Western; Bone Marrow Cells; Carrier Proteins; Cathepsin K; Cathepsins; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Proliferation; Cells, Cultured; Chromones; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p18; Cyclin-Dependent Kinase Inhibitor p19; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Enzyme Inhibitors; Femur; Flavonoids; Gene Expression; Imidazoles; Isoenzymes; Macrophage Colony-Stimulating Factor; Macrophages; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Osteoclasts; Osteopetrosis; Pyridines; Radiography; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Reverse Transcriptase Polymerase Chain Reaction; Tartrate-Resistant Acid Phosphatase; Tumor Suppressor Proteins | 2004 |